Non-small cell lung cancer is a type of epithelial lung cancer. The different subtypes of non-small cell lung cancer include adenocarcinoma, squamous cell carcinoma, large-cell carcinoma, and other subtypes such as adenosquamous carcinoma and sarcomatoid carcinoma.
Most of non-small cell lung cancer treatment guidelines recommended need biomarker testing of tumor samples as part of the routine diagnosis, prior to initiating therapy in the first-line setting. Predictive biomarkers provide information about the effect of a therapeutic intrusion. The use of biomarkers has become important because it helps in the development of cost-effective therapies with improved clinical benefits.
Download the Free Sample Report @ https://bit.ly/2Uplrwv
Chemotherapy may result in toxic effects, which can lead to a large burden of morbidity. Similarly, targeted therapies may cause the same level of toxicity as chemotherapy. Therefore, the use of predictive biomarkers can reduce unnecessary treatment and adverse effects. The development of anti-EGFR drugs such as gefitinib and erlotinib is one of the examples of drug development using biomarkers that are approved for advanced stage non-small cell lung cancer. Hence, the use of predictive biomarkers for the development of cost-effective therapies is one of the key trends in the global non-small cell lung cancer drugs market to grow at a CAGR of 13.16% during the forecast period.
Comments